CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

18-998/S-064

CONTENTS

Reviews / Information Included in this NDA Review.	
Approval Letter	X
Approvable Letter	
Final Printed Labeling	
Medical Review(s)	
Chemistry Review(s)	X
EA/FONSI	
Pharmacology Review(s)	
Statistical Review(s)	
Microbiology Review(s)	
Clinical Pharmacology/ Biopharmaceutics Review(s)	
Administrative Document(s)	X
Correspondence	X
Bioresearch Monitoring	

CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER(S)

NDA 18-998/S-064

Trade Name: Vasotec

Generic Name(s): (enalaprilat)

Sponsor: Biovail Laboratories Inc.

Agent:

Approval Date: October 10, 2002

Indication: The treatment of hypertension.

CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER

NDA 18-998/S-064

Approval Letter(s)

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 18-998 / S-064

Biovail Laboratories Inc.
[redacted]

Dear [redacted]

Please refer to your supplemental new drug application dated August 13, 2002, received August 15, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Vasotec ™ (enalapril maleate) Tablets, 2.5mg, 5mg, 10 mg, 20mg and 40mg.

This "Changes Being Effected in 30 Days" supplemental new drug application provides for [redacted] as an alternate release and stability testing facility for Vasotec ™ tablets.

We have completed the review of this supplemental application, and it is approved.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Alisea Sermon, Regulatory Health Project Manager, at (301) 594-5334.

Sincerely,

{See appended electronic signature page}

Kasturi Srinivasachar, Ph.D.
Chemistry Team Leader, DNDC I for the
Division of Cardio-Renal Drug Products, (HFD-110)
DNDC I, Office of New Drug Chemistry
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Kasturi Srinivasachar
10/10/02 09:50:00 AM

CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER

NDA 18-998/S-064

Chemistry Review(s)

CHEMIST'S REVIEW	1. ORGANIZATION HFD-110, Div. Of Cardio-Renal Drug Products	2. NDA Number 18-998
3. Name and Address of Applicant (City & State) c/o Biovail Technologies Limited 3725 Concorde Parkway Chantilly, VA 20151		4. Supplement(s) Number(s) Date(s) SCM-064 08-13-2002
5. Drug Name Vasotec™	6. Nonproprietary Name Enalapril Maleate	7. Amendments & Other (reports, etc) - Dates None
8. Supplement Provides For: [redacted] as an alternate release and stability testing facility for Vasotec™.		
9. Pharmacological Category Hypertension	10. How Dispensed Rx _✔_ OTC ___	11. Related IND(s)/ NDA(s)/DMF(s)
12. Dosage Form(s)/Route of Admin. Solid dosage/Oral	13. Potency(ies) 2.5 mg, 5 mg, 10 mg, 20 mg, 40 mg	
14. Chemical Name and Structure  $C_{20}H_{28}N_2O_5.C_4H_4O_4$ 492.52 L-Proline, 1-[N-[1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-, (S)-, (Z)-2-butenedioate (1:1)		15. Records/Reports Current: Yes ____ No ____ Reviewed: Yes ____ No ____

Comments: This application was filed as a PAC-ATLS (Post Approval Changes – Analytical Testing Laboratory Sites) supplement. It is a CBE-30 (Changes Being Effected in 30 Days) supplement. Biovail provides a summary of Approved Test Methods and Acceptance Criteria for the Release and Stability of Vasotec™ tablets. FDA has inspected the [redacted] between Feb 1-2, 2001 and classified it as acceptable. The firm also provides an environmental impact request for a categorical exclusion, which is considered by this reviewer to be acceptable..

17. **Conclusions and Recommendations:** All post approval commitments relating to the test methods have been fulfilled. The office of compliance has given an overall acceptable recommendation for the new testing site [redacted].This application is recommended for approval from the standpoint of chemistry, manufacturing and controls.

18. **REVIEWER**

Name	Signature	Date Completed 8/27/02
Kris Raman, Ph.D.		

2 Page(s) Withheld

X § 552(b)(4) Trade Secret / Confidential

___ § 552(b)(5) Deliberative Process

___ § 552(b)(4) Draft Labeling

ESTABLISHMENT EVALUATION REQUEST

SUMMARY REPORT

Application : NDA 18998/064
Org Code : 110
Priority : 1P

Sponsor: BIOVAIL LABS
3725 CONCORDE PKY
CHANTILLY, VA 20151

Stamp Date : 15-AUG-2002
PDUFA Date : 15-FEB-2003
Action Goal :
District Goal: 11-JAN-2003

Brand Name : VASOTEC
Estab. Name:
Generic Name: ENALAPRIL MALEATE
Dosage Form: (TABLET)
Strength : 2.5MG,5,10 & 20MG

FDA Contacts:			
A. SERMON	Project Manager	(HFD-110)	
K. RAMAN	Review Chemist	(HFD-110)	301-594-5351
K. SRINIVASACHAR	Team Leader	(HFD-110)	301-594-5376

Overall Recommendation: ACCEPTABLE on 27-AUG-2002by J. D AMBROGIO(HFD-324) 301-827-0062

Establishment : [redacted]

DMF No:

Responsibilities: FINISHED DOSAGE RELEASE TESTER
FINISHED DOSAGE STABILITY TESTER

Profile : CTL
OAI Status: NONE
Last Milestone: OC RECOMMENDATION
Milestone Date: 27-AUG-02
Decision : ACCEPTABLE
Reason : BASED ON PROFILE

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Kris Raman
9/13/02 09:14:19 AM
CHEMIST

Kasturi Srinivasachar
9/13/02 10:21:30 AM
CHEMIST

CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER

NDA 18-998/S-064

Administrative/Correspondence

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 18-998/S-064

Biovail Laboratories Incorporated
Attention: Mr. Niall Morrissey
c/o Biovail Technologies Limited
3725 Concorde Parkway
Chantilly, VA

Dear Mr. Morrissey:

We have received your supplemental drug application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

Name of Drug Product: Vasotec (Enalapril Maleate) Tablets

NDA Number: 18-998

Supplement number: S-064

Date of supplement: August 13, 2002

Date of receipt: August 15, 2002

Unless we notify you within 60 days of the receipt date that the application is not sufficiently complete to permit a substantive review, this application will be filed under section 505(b) of the Act on October 14,2002 in accordance with 21 CFR 314.101(a).

All communications concerning this supplement should be addressed as follows:

U.S. Postal Service:
Center for Drug Evaluation and Research
Division of Cardio-Renal Drugs Products, HFD-110
Attention: Division Document Room
5600 Fishers Lane
Rockville, Maryland 20857

Courier/Overnight Mail:
Food and Drug Administration
Center for Drug Evaluation and Research
Division of Cardio-Renal Drugs Products, HFD-110
Attention: Document Room
1451 Rockville Pike
Rockville, Maryland 20852

If you have any question, please call:

Ms. Alisea Sermon, Pharm.D.
Regulatory Project Manager
(301) 594-5334

Sincerely yours,

Zelda McDonald
Acting Chief, Project Management Staff
Division of Cardio-Renal Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

cc: [redacted]

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Zelda McDonald
8/22/02 03:26:30 PM